Speaker: Daniel Pollyea

0:01:13

Addressing whether AML with monocytic features should be considered a distinct clinical entity

0:01:20

Omacetaxine and azacitidine for newly diagnosed patients with MDS and excess blasts

0:01:06

Ongoing MDS clinical trials to look out for

0:01:08

The importance of predicting venetoclax response in patients with AML

0:01:50

Treating patients with poor-risk cytogenetics with venetoclax and HMAs

0:01:01

Novel treatment paradigms for AML at ASH 2021

0:01:00

The potential use of multi-gene molecular MRD testing in AML

0:01:57

Glasdegib as maintenance therapy in AML and MDS

0:01:12

Varied outcomes in patients with AML harboring poor-risk cytogenetics with or without TP53 mutation

0:01:34

Exploiting the metabolic vulnerabilities of MDS stem cells

0:01:43

Targeting MDS stem cells with omacetaxine and azacitidine

0:01:48

IDH1 inhibitor ivosidenib for the treatment of relapsed/ refractory AML

0:01:29

Venetoclax plus azacitidine for newly diagnosed younger AML

0:02:31

IDH mutations in AML treated with venetoclax

0:02:25

Venetoclax for AML

0:02:16

allo-SCT improves survival following venetoclax and azacitidine therapy in AML

0:02:49

Venetoclax and azacitidine for young patients with AML

0:00:46

A next-generation CD33-directed ADC for AML

0:01:11

Results and rational behind breakthrough therapy-designated E-selectin antagonist for AML

0:01:30

AML & Myelodysplasia breakthrough

0:02:04

Emerging therapies in AML: why patients should be optimistic

0:01:07

Challenges in treating AML

1:17:29

AML Non-Transplant Options: What's in the Pipeline? (2018)

0:01:33

Phase I trial results for oral azacitidine and venetoclax in R/R AML